Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug

Eli Lilly, AstraZeneca Launch Pivotal Clinical Trial For Early Alzheimer’s Disease Drug
Alzheimer’s ResearchEli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer's disease. Alzheimer’s disease is characterized by two important pathological features -- amyloid-β plaques and neurofibrillary tangles -- and is the most frequent form of dementia, contributing for 60 to 80% of dementia cases. In the United States, Alzheimer’s is a major health challenge, since approximately 5 million Americans older than 65 years old are affected by the disease. Alzheimer's is an economic and social burden not only for U.S. but also for many other developed nations. The U.S. alone incurs costs upwards of $200 billion dollars annually on the disease and it is estimated that the expenditure will increase to more than $1 trillion dollars by 2050. Therefore, there is an urgent need for the development of new treatments to decrease the progression of the disease and increase the delay of the debilitating associated-dementia. The AMARANTH Phase II/III clinical trial will evaluate the safety and efficacy of oral AZD3293/LY3314814 against placebo and will
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *